연구동향 분석
박사

The role of CYP3A5 and MDR1 genetic polymorphisms in population pharmacokinetics of felodipine in healthy Korean subjects = 건강한 한국인에 있어 CYP3A5 및 MDR1 유전적 다형성에 따른 펠로디핀의 집단 약동학적 특성

트란띠프헝 2018년

논문상세정보
인용/피인용
' The role of CYP3A5 and MDR1 genetic polymorphisms in population pharmacokinetics of felodipine in healthy Korean subjects = 건강한 한국인에 있어 CYP3A5 및 MDR1 유전적 다형성에 따른 펠로디핀의 집단 약동학적 특성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 약리학과 치료학
  • CYP3A5
  • Felodipine
  • Population pharmacokinetic
  • mdr1
  • nonmem
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
802 0

0.0%

' The role of CYP3A5 and MDR1 genetic polymorphisms in population pharmacokinetics of felodipine in healthy Korean subjects = 건강한 한국인에 있어 CYP3A5 및 MDR1 유전적 다형성에 따른 펠로디핀의 집단 약동학적 특성' 의 참고문헌

  • von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivist KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172–83. doi: 10.1016/j.clpt.2003.10.008
  • van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668–71.
  • Zhou H (2003) Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43:211–27.
  • Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ (2002) The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63:765–70.
  • Yoo H-D, Lee Y-B (2011) Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. Arch Pharm Res 34:1817–28. doi: 10.1007/s12272-011-1104-1
  • Yin OQP, Tomlinson B, Chow MSS (2009) Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men. Clin Ther 31:999–1006. doi: 10.1016/j.clinthera.2009.05.014
  • Yedinak KC, Lopez LM (1991) Felodipine: a new dihydropyridine calcium-channel antagonist. DICP 25:1193–206.
  • Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T (2004) CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19:120–9.
  • Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165–175. doi: 10.1007/BF01117450
  • Xiang Q, Li C, Zhao X, Cui YM (2017) The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther 42:345–349. doi: 10.1111/jcpt.12505
  • Wu, C.Y., Benet, L.Z., 2005. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23.
  • Wolf SJ, Bachtiar M, Wang J, Sim TS, Chong SS, Lee CGL (2011) An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. Pharmacogenomics J 11:315–325. doi: 10.1038/tpj.2011.16
  • Wingstrand K, Abrahamsson B, Edgar B (1990) Bioavailability from felodipine extended-release tablets with different dissolution properties. Int J Pharm 60:151–156. doi: 10.1016/0378-5173(90)90301-J
  • Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475–90.
  • Wester A, Lorimer AR, Westberg B (1991) Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin 12:275–81. doi: 10.1185/03007999109112661
  • Weidolf L, Borg KO, Hoffmann KJ (1984) Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica 14:657–66. doi: 10.3109/00498258409151463
  • Wang Z, Xiang Q, Cui Y, Zhao X, Zhou Y (2013) The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet 28:239–43.
  • Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5’-promoter region polymorphism. Clin Pharmacol Ther 68:82–91. doi: 10.1067/mcp.2000.108506
  • Wacher VJ, Wu C-Y, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134. doi: 10.1002/mc.2940130302
  • Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322–30. doi: 10.1021/js980082d
  • Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809–812. doi: 10.1007/s00228-003-0567-5
  • Thummel KE (2007) Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117:3173–6. doi: 10.1172/JCI34007
  • Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735–8.
  • Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–43.
  • Soons PA, de Boer AG, van Brummelen P, Breimer DD (1989) Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. Br J Clin Pharmacol 27:179–89.
  • Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ (1999) Grapefruit juice activates P-glycoprotein-mediate drug transport. Pharm Res 16:478– 485. doi: 10.1023/A:1011902625609
  • Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B (2007) CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 29:412–6. doi: 10.1097/FTD.0b013e31811f390a
  • Sills GJ, Kwan P, Butler E, de Lange ECM, van den Berg D-J, Brodie MJ (2002) Pglycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 3:427–432. doi: 10.1016/S1525-5050(02)00511-5
  • Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1. N Engl J Med 348:1442–1448. doi: 10.1056/NEJMoa021986
  • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
  • Schulman DS, Flores AR, Tugoen J, Dianzumba S, Reichek N (1996) Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Am J Cardiol 78:56–60.
  • Schinkel AH, Kemp S, Doll M, Rudenko G, Wagenaar E (1993) N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268:7474–81.
  • Salama NN, Yang Z, Bui T o. t., Ho RJY (2006) MDR1 haplotypes significantly minimize intracellular uptake and transcellular P‐gp substrate transport in recombinant LLC‐PK1 cells. J Pharm Sci 95:2293–2308. doi: 10.1002/jps.20717
  • Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, Liew EL, Sakaeda T, Yoshiura K-I, Niikawa N, Sakurai M, Ishikawa T (2007) Quantitative structure-- activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (Pglycoprotein/MDR1). Biochemistry 46:7678–93. doi: 10.1021/bi700330b
  • Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400–4.
  • Sabnis S (1999) Factors influencing the bioavailability of peroral formulations of drugs for dogs. Vet Res Commun 23:425–47.
  • Roy J-N, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M (2005) CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33:884–7. doi: 10.1124/dmd.105.003822
  • Robertson DR, Waller DG, Renwick AG, George CF (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 25:297– 305.
  • Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448. doi: 10.1081/DMR-120001392
  • Pouton CW (2006) Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278–287. doi: 10.1016/j.ejps.2006.04.016
  • Plummer SJ, Conti D V, Paris PL, Curran AP, Casey G, Witte JS (2003) CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 12:928–32.
  • Pharmacokinetics P (1999) Guidance for Industry Population Pharmacokinetics. 20852– 1448.
  • Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6. doi: 10.1124/dmd.105.008672
  • Ono Y, Mizuno K, Goto M, Hashimoto S, Watanabe T (1999) Hemodynamic and antihypertensive effects of felodipine in patients with essential hypertension: A pilot study. Curr Ther Res 60:392–401. doi: 10.1016/S0011-393X(99)80017-4
  • Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., Nebert, D. W., 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1–42.
  • Nelson DR (2006) Cytochrome P450 nomenclature, 2004. Methods Mol Biol 320:1–10. doi: 10.1385/1-59259-998-2:1
  • Navadiya K, Tiwari S (2015) Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris. Curr Drug Saf 10:194–201.
  • Muller JE (1999) Circadian variation in cardiovascular events. Am J Hypertens 12:35S– 42S.
  • Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098. doi: 10.1056/NEJM198710223171717
  • Monopoli A, Forlani A, Milani S, Ongini E (1988) Antihypertensive effect of spirapril and felodipine during repeated administration to spontaneously hypertensive rats. Pharmacol Res Commun 20:37–47. doi: 10.1016/S0031-6989(88)80605-2
  • Min DI, Ellingrod VL (2003) Association of the CYP3A4*1B 5’-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 25:305–9.
  • Meyer UA (2004) Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669–76. doi: 10.1038/nrg1428
  • Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 21:27–30. doi: 10.1016/j.yebeh.2011.02.015
  • McDonnell AM, Dang CH (2013) Basic review of the cytochrome p450 system. J Adv Pract Oncol 4:263–8.
  • Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14. doi: 10.1046/j.1365-2125.2003.02007.x
  • Mahmoud M, Abdel-Kader R, Hassanein M, Saleh S, Botros S (2007) Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. Eur J Pharmacol 569:222–7. doi: 10.1016/j.ejphar.2007.04.061
  • MacPhee IAM, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW (2005) Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation 79:499–502. doi: 10.1097/01.TP.0000151766.73249.12
  • MOULY S, MATHENY C, PAINE M, SMITH G, LAMBA J, LAMBA V, PUSEK S, SCHUETZ E, STEWART P, WATKINS P (2005) Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78:605–618. doi: 10.1016/j.clpt.2005.08.014
  • Ljung B (1985) Vascular selectivity of felodipine. Drugs 29 Suppl 2:46–58.
  • Leenen FHH, Holliwell DL (1992) Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 69:639–645. doi: 10.1016/0002-9149(92)90156-S
  • Lawes CM, Hoorn S Vander, Rodgers A (2008) Global burden of blood-pressure-related disease, 2001. Lancet 371:1513–1518. doi: 10.1016/S0140-6736(08)60655-8
  • Landahl S, Edgar B, Gabrielsson M, Larsson M, Lernfelt B, Lundborg P, Reg rdh CG (1988) Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin Pharmacokinet 14:374–83. doi: 10.2165/00003088-198814060-00004
  • Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB (2012) PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 22:555–8. doi: 10.1097/FPC.0b013e328351d47f
  • Lakhman SS, Ma Q, Morse GD (2009) Pharmacogenomics of CYP3A : considerations for HIV treatment. Pharmacogenomics 10:1323–1339. doi: 10.2217/pgs.09.53
  • Kuehl P, Zhang J, Lin Y, et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–91. doi: 10.1038/86882
  • Kr mer SD, Wunderli-Allenspach H (2001) Physicochemical properties in pharmacokinetic lead optimization. Farm 56:145–148. doi: 10.1016/S0014- 827X(01)01028-X
  • Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstr m RH, Perlmann T, Lehmann JM (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82.
  • Kivist KT, Niemi M, Schaeffeler E, Pitk l K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523–5.
  • Kim RB, Leake BF, Choo EF, Dresser GK, Kubba S V, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–99. doi: 10.1067/mcp.2001.117412
  • Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223. doi: 10.1016/S0140-6736(05)17741-1
  • Katz AM (1986) Pharmacology and mechanisms of action of calcium-channel blockers. J Clin Hypertens 2:28S–37S.
  • Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta - Biomembr 455:152–162. doi: 10.1016/0005-2736(76)90160-7
  • Hsiao C-L, Wu Y-C, Hsu K-Y (2011) Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: A retrospective review. Arzneimittelforschung 61:444–51.
  • Hoffmeyer S (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 97:3473–3478. doi: 10.1073/pnas.050585397
  • Hoffmann K-J, Andersson L (1987) Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers. Drugs 34:43–52. doi: 10.2165/00003495-198700343-00010
  • Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K, Chiba K, Nanba E, Oshimura M, Sato T, Higuchi S, Otsubo K (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 13:2959–2969. doi: 10.1093/hmg/ddh313
  • Hesselink DA, van Gelder T, van Schaik RHN, Balk AHMM, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RAA (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76:545–56. doi: 10.1016/j.clpt.2004.08.022
  • H rter D, Dressman JB (2001) Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 46:75–87.
  • Guo L-Q, Chen Q-Y, Wang X, Liu Y-X, Chu X-M, Cao X-M, Li J-H, Yamazoe Y (2007) Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. Curr Drug Metab 8:623–30.
  • Guengerich FP, Brian WR, Iwasaki M, Sari MA, B rnhielm C, Berntsson P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34:1838–44.
  • Gradman AH (1993) Treatment of hypertension with felodipine in patients with concomitant diseases. Clin Cardiol 16:294–301.
  • Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860–71. doi: 10.1016/j.bbapap.2009.02.014
  • Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331–4.
  • Frohlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE (2004) Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 58:443–444. doi: 10.1111/j.1365- 2125.2004.02159.x
  • Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira MEW, Pires RC, Hutz MH (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78:551–8. doi: 10.1016/j.clpt.2005.08.003
  • Felle K, Persson B, Vessman J (1984) Dissolution test for felodipine tablets using chemical oxidation in situ to maintain “sink conditions.” J Pharm Biomed Anal 2:527– 536. doi: 10.1016/0731-7085(84)80056-4
  • Fagan TC (1997) Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. The felodipine ER in the elderly versus young working group. J Am Geriatr Soc 45:712–7.
  • Edgar B, Regardh C, Attman P, Aurell M, Herlitz H, Johnsson G (1989) Pharmacokinetics of felodipine in patients with impaired renal function. Br J Clin Pharmacol 27:67–74. doi: 10.1111/j.1365-2125.1989.tb05336.x
  • Edgar B, Reg rdh CG, Johnsson G, Johansson L, Lundborg P, L fberg I, R nn O (1985) Felodipine kinetics in healthy men. Clin Pharmacol Ther 38:205–11.
  • Edgar B, Lundborg P, Reg rdh CG (1987) Clinical pharmacokinetics of felodipine. A summary. Drugs 34(3):16–27.
  • Dunselman PH, Edgar B (1991) Felodipine clinical pharmacokinetics. Clin Pharmacokinet 21:418–30. doi: 10.2165/00003088-199121060-00003
  • Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG (2001) CDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386– 92.
  • Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–73. doi: 10.1146/annurev.pharmtox.43.100901.140251
  • Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG (1984) A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm 21:167–177. doi: 10.1016/0378-5173(84)90091-7
  • Daly AK (2010) Pharmacogenetics and human genetic polymorphisms. Biochem J 429:435–449. doi: 10.1042/BJ20100522
  • Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31. doi: 10.2165/00003088-200645010-00002
  • Dally H, Bartsch H, J ger B, Edler L, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Kayser K, Schulz V, Risch A (2004) Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett 207:95–9. doi: 10.1016/j.canlet.2003.12.011
  • Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41.
  • Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89–95.
  • Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–74. doi: 10.1067/mcp.2001.114164
  • Carrasco JCA-, Portugal M del CC, Murrieta FJF, Quinteros SC- (2015) Oral pharmacokinetics of felodipine in Mexican healthy volunteers: Evidence for interethnic differences. Int J Pharmacol 11:382–386. doi: 10.3923/ijp.2015.382.386
  • Campbell NRC, Lackland DT, Lisheng L, Niebylski ML, Nilsson PM, Zhang X-H (2015) Using the global burden of disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the world hypertension league. J Clin Hypertens (Greenwich) 17:165–7. doi: 10.1111/jch.12479
  • Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ (1998) The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 4:92–6.
  • Buchman BP, Sallis JF, Criqui MH, Dimsdale JE, Kaplan RM (1991) Physical activity, physical fitness, and psychological characteristics of medical students. J Psychosom Res 35:197–208.
  • Blychert E, Wingstrand K, Edgar B, Lidman K (1990) Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. Br J Clin Pharmacol 29:39–45.
  • Blychert E, Edgar B, Elmfeldt D, Hedner T (1991) A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 31:15–24.
  • Blowey DL, Moncica I, Scolnik D, Arbus GS, H bert D, Balfe JW, Koren G (1996) The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 50:147–148. doi: 10.1007/s002280050083
  • Benet LZ, Cummins CL (2001) The drug efflux–metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50:S3–S11. doi: 10.1016/S0169-409X(01)00178-8
  • Benet L, Cummins C, Wu C (2003) Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393–398. doi: 10.2174/1389200033489389
  • Balram C, Zhou Q, Cheung YB, Lee EJD (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59:123–6. doi: 10.1007/s00228-003-0594-2
  • Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter M-H, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889–96.
  • Ambudkar S V, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–98. doi: 10.1146/annurev.pharmtox.39.1.361
  • Akaike H (1974) A New Look at the Statistical Model Identification. pp 215–222
  • Abrahamsson B, Alpsten M, Hugosson M, Jonsson UE, Sundgren M, Svenheden A, T lli J (1993) Absorption, gastrointestinal transit, and tablet erosion of felodipine extendedrelease (ER) tablets. Pharm Res 10:709–14.
  • Aarons L (1991) Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 32:669–70.
  • (2013) WHO | A global brief on hypertension. In: WHO. http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf. Accessed 26 Oct 2017